Adempa-M 5 mg+500 mg (Tablet)
Unit Price: ৳ 20.00 (3 x 10: ৳ 600.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin metformin hydrochloride |
| Company | Unimed unihealth pharmaceuticals ltd |
Therapeutic Class
- Combination Oral hypoglycemic preparations
Indications
- Treatment of adults with type 2 diabetes mellitus
- Adjunct to diet and exercise
- Patients insufficiently controlled on maximally tolerated dose of Metformin alone
- In combination with other medicinal products for the treatment of diabetes
- In patients already being treated with the combination of Empagliflozin and Metformin as separate tablets
Pharmacology
- Empagliflozin is an inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
- Reduces renal reabsorption of filtered glucose
- Lowers the renal threshold for glucose
- Increases urinary glucose excretion
- Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug
- Lowers basal and postprandial plasma glucose
- Does not produce hypoglycemia
- Decreases hepatic glucose production
- Decreases intestinal absorption of glucose
- Improves insulin sensitivity
Dosage & Administration
- Individualized based on effectiveness and tolerability
- Take twice daily with meals
- Dose escalation should be gradual
- Maximum recommended daily dose of Metformin Hydrochloride is 2000 mg
- Maximum recommended daily dose of Empagliflozin is 25 mg
- Extended-release formulations available
- Individualize starting dose based on the patient’s current drug regimen
- Adjust dosing based on effectiveness and tolerability
- Renal impaired patient assessment required
- Safety and effectiveness not established in pediatric patients under 18 years of age
Interaction
- Co-administration with diuretics
- Co-administration with insulin or insulin secretagogues
- Monitoring glycemic control with urine glucose tests not recommended
- Drugs that reduce Metformin clearance
- Carbonic Anhydrase Inhibitors interaction
- Drugs affecting glycemic control
- Alcohol interaction
Contraindications
- Hypersensitivity to Empagliflozin and Metformin
- Acute metabolic acidosis
- Diabetic pre-coma
- Severe renal failure
- Acute conditions with potential to alter renal function
- Disease which may cause tissue hypoxia
- Hepatic impairment
- Acute alcohol intoxication
Side Effects
- Urinary tract infection
- Female genital mycotic infections
- Diarrhea
- Nausea/vomiting
- Flatulence
- Abdominal discomfort
- Indigestion
- Asthenia
- Headache
- Hypoglycemia
- Vaginal moniliasis
- Vulvovaginitis
- Balanitis and other genital infection
- Thirst
- Taste disturbance
- Pruritus
- Rash
- Increased urination
- Increased serum lipids
- Volume depletion
- Urticaria
- Dysuria
- Increased blood creatinine/Glomerular filtration rate
- Increased haematocrit
- Diabetic ketoacidosis
Pregnancy & Lactation
- Potential risk to fetus
- Not recommended for breastfeeding
Precautions & Warnings
- Lactic Acidosis
- Hypotension
- Ketoacidosis
- Acute kidney injury
- Urosepsis
- Pyelonephritis
- Fournier’s gangrene
- Genital mycotic infections
- Hypoglycemia risk
- Vitamin B12 Deficiency
- Increased LDL-C
- Macrovascular Outcomes
Overdose Effects
- No toxicity seen at highest recommended doses
- Lactic acidosis is a medical emergency
- Hemodialysis for effective removal
Storage Conditions
- Keep below 30°C
- Protected from light & moisture
- Keep out of the reach of children
Related Brands
- Glifo-M XR 5 mg+1000 mg (Tablet (Extended Release)) - acme-laboratories-ltd
- Emfogen M 5 mg+1000 mg (Tablet) - general-pharmaceuticals-ltd
- Emfogen M 12.5 mg+500 mg (Tablet) - general-pharmaceuticals-ltd
- Emfogen M 12.5 mg+1000 mg (Tablet) - general-pharmaceuticals-ltd
- Emazid M 12.5 mg+500 mg (Tablet) - eskayef-pharmaceuticals-ltd